These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37731486)

  • 21. Retraction: Plumbagin Ameliorates Collagen-Induced Arthritis by Regulating Treg/Th17 Cell Imbalances and Suppressing Osteoclastogenesis.
    Frontiers Editorial Office
    Front Immunol; 2020; 11():112. PubMed ID: 32038665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
    Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
    Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Makita S; Yoshimura K; Tobinai K
    Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities.
    Weinkove R; George P; Ruka M; Haira TH; Giunti G
    N Z Med J; 2021 Sep; 134(1542):96-108. PubMed ID: 34531588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.
    Su T; Ying Z; Lu XA; He T; Song Y; Wang X; Ping L; Xie Y; Tu M; Liu G; Qi F; Ding Y; Jing H; Zhu J
    Cryobiology; 2020 Oct; 96():106-113. PubMed ID: 32721392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retraction: Inhibition of Bcl2L12 attenuates eosinophilia-related inflammation in heart.
    Frontiers Editorial Office
    Front Immunol; 2023; 14():1227707. PubMed ID: 37342336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy.
    Vercellino L; de Jong D; di Blasi R; Kanoun S; Reshef R; Schwartz LH; Dercle L
    Front Oncol; 2021; 11():664688. PubMed ID: 34123825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retraction: Harnessing TRAIL-induced apoptosis pathway for cancer immunotherapy and associated challenges.
    Frontiers Editorial Office
    Front Immunol; 2023; 14():1285126. PubMed ID: 37731508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
    Munshi PN; Ujjani C
    Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retraction: Akt2 Regulates the Differentiation and Function of NKT17 Cells
    Frontiers Editorial Office
    Front Immunol; 2021; 12():686304. PubMed ID: 33868320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retraction: Dysregulation of survivin-targeting microRNAs in autoimmune diseases: new perspectives for novel therapies.
    Frontiers Editorial Office
    Front Immunol; 2023; 14():1285591. PubMed ID: 37731499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retraction: Corrigendum: Akt2 Regulates the Differentiation and Function of NKT17 Cells
    Frontiers Editorial Office
    Front Immunol; 2021; 12():716458. PubMed ID: 34194444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice.
    Sengsayadeth S; Savani BN; Oluwole O; Dholaria B
    EJHaem; 2022 Jan; 3(Suppl 1):6-10. PubMed ID: 35844299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma.
    Jackson Z; Hong C; Schauner R; Dropulic B; Caimi PF; de Lima M; Giraudo MF; Gupta K; Reese JS; Hwang TH; Wald DN
    Cancer Discov; 2022 Aug; 12(8):1886-1903. PubMed ID: 35554512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges.
    Narkhede M; Mehta A; Ansell SM; Goyal G
    Ann Transl Med; 2021 Jun; 9(12):1036. PubMed ID: 34277836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy.
    Fang PQ; Gunther JR; Wu SY; Dabaja BS; Nastoupil LJ; Ahmed S; Neelapu SS; Pinnix CC
    Front Oncol; 2021; 11():648655. PubMed ID: 33842363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retraction: Curcumin Blunts IL-6 Dependent Endothelial-to-Mesenchymal Transition to Alleviate Renal Allograft Fibrosis Through Autophagy Activation.
    Frontiers Editorial Office
    Front Immunol; 2021; 12():818539. PubMed ID: 34899767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.